Erste Group Bank Estimates Gilead Sciences FY2026 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Erste Group Bank increased their FY2026 earnings per share estimates for shares of Gilead Sciences in a research note issued to investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will post earnings per share of ($0.74) for the year, up from their prior estimate of ($0.75). The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.77) per share. Erste Group Bank also issued estimates for Gilead Sciences’ FY2027 earnings at $9.65 EPS.

Several other research analysts also recently commented on GILD. Rothschild & Co Redburn lowered their target price on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Leerink Partners decreased their price target on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Monday, July 6th. Finally, Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $159.04.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $133.21 on Monday. Gilead Sciences has a twelve month low of $107.75 and a twelve month high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The stock’s 50-day simple moving average is $129.72 and its 200 day simple moving average is $135.37. The firm has a market capitalization of $165.39 billion, a PE ratio of 18.15 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the previous year, the firm earned $1.81 EPS. Gilead Sciences’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Norges Bank acquired a new stake in Gilead Sciences in the fourth quarter worth $2,617,152,000. Boston Partners bought a new stake in Gilead Sciences in the fourth quarter valued at $517,808,000. Massachusetts Financial Services Co. MA raised its holdings in shares of Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after purchasing an additional 4,113,999 shares during the period. Bank of America Corp DE raised its holdings in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after purchasing an additional 3,046,688 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares in the company, valued at $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 77,000 shares of company stock valued at $9,978,740. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s payout ratio is 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.